These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 24997182

  • 1. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
    Boyer DS, Goldbaum M, Leys AM, Starita C, V.I.S.I.O.N. Study Group.
    Br J Ophthalmol; 2014 Nov; 98(11):1543-6. PubMed ID: 24997182
    [Abstract] [Full Text] [Related]

  • 2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP, Haji SA, Frenkel RE.
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [Abstract] [Full Text] [Related]

  • 3. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
    Frenkel RE, Mani L, Toler AR, Frenkel MP.
    Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
    [Abstract] [Full Text] [Related]

  • 4. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, Freund KB.
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [Abstract] [Full Text] [Related]

  • 5. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
    Lemos V, Cabugueira A, Noronha M, Abegão Pinto L, Reina M, Branco J, Gomes T.
    Ophthalmologica; 2015 Jan; 233(3-4):162-8. PubMed ID: 25791262
    [Abstract] [Full Text] [Related]

  • 6. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
    Hariprasad SM, Shah GK, Blinder KJ.
    Am J Ophthalmol; 2006 Jan; 141(1):200-1. PubMed ID: 16387003
    [Abstract] [Full Text] [Related]

  • 7. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB.
    J Glaucoma; 2012 Jan; 21(4):241-7. PubMed ID: 21423038
    [Abstract] [Full Text] [Related]

  • 8. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
    Lanzl IM, Maier M, Feucht N, Lohmann CP, Kotliar KE.
    Am J Ophthalmol; 2008 Jan; 145(1):185; author reply 186. PubMed ID: 18154762
    [No Abstract] [Full Text] [Related]

  • 9. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, Yoon YH.
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [Abstract] [Full Text] [Related]

  • 10. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ, Moshfeghi DM, Francom S, Rundle AC, Reshef DS, Lee PP, Schaeffer C, Rubio RG, Lai P.
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [Abstract] [Full Text] [Related]

  • 11. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, Gorin MB.
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [Abstract] [Full Text] [Related]

  • 12. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
    Murray CD, Wood D, Allgar V, Walters G, Gale RP.
    Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
    [Abstract] [Full Text] [Related]

  • 13. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
    Kim JE, Mantravadi AV, Hur EY, Covert DJ.
    Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
    [Abstract] [Full Text] [Related]

  • 14. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 15. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W, Montriwet M.
    PLoS One; 2015 Jun; 10(9):e0137833. PubMed ID: 26360382
    [Abstract] [Full Text] [Related]

  • 16. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema.
    Al-Abdullah AA, Nowilaty SR, Asghar N, Al-Kharashi AS, Ghazi NG.
    Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810
    [Abstract] [Full Text] [Related]

  • 17. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB.
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [Abstract] [Full Text] [Related]

  • 18. SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?
    Dedania VS, Bakri SJ.
    Retina; 2015 May; 35(5):841-58. PubMed ID: 25905784
    [Abstract] [Full Text] [Related]

  • 19. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study.
    Knip MM, Välimäki J.
    Acta Ophthalmol; 2012 May; 90(3):254-8. PubMed ID: 20456259
    [Abstract] [Full Text] [Related]

  • 20. Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).
    Ishibashi T, LEVEL-J Study Group.
    Jpn J Ophthalmol; 2013 Sep; 57(5):417-23. PubMed ID: 23860781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.